Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797679 | 0.93 | RAB9A (0.48) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL9381176 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL9381172 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL9389295 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL8797508 | 0.85 | GAA (0.45) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL18056303 | 0.85 | GAA (0.49) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL9386410 | 0.83 | RAB9A (0.36) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL3248801 | 0.83 | GPR119 (0.42) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL9388775 | 0.83 | GAA (0.50) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL30677893 | 0.83 | GAA (0.52) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| US-6531466-B2 | E.g., a 1-aza-10-(1-hydroxyethyl-11-oxo-4-(het-methylene)-tricyclo(7.2 .0.0(3,8))undec-2-ene-2-carboxylate; good activity against grampositive bacteria such as methicillin-resistant Staphylococcus aureus and epidermidis | GLAXOSMITHKLINE SPA (IT) | 2003-03-11 | — | — | US | disclosed |
| EP-0937078-B1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2003-02-12 | — | — | EP | disclosed |
| US-20010047094-A1 | Tricyclic carbapenem compounds | GLAXO WELLCOME SPA | 2001-11-29 | — | — | US | disclosed |
| EP-0937078-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.p.A. (IT) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021210-A1 | TRICYCLIC CARBAPENEM COMPOUNDS | GLAXO WELLCOME S.P.A. (IT) | 1998-05-22 | — | — | WO | disclosed |
| US-5693807-A | Substituted hydroquinone derivatives | CIBA-GEIGY CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0394991-B1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| CN-1089253-A | The hydroquinone derivatives that replaces | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4743598-A | Antibacterial 2-(azacycloalkyl) penems | SCHERING CORPORATION (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0109044-B1 | PENEMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0109044-A1 | Penems, pharmaceutical compositions containing them, process for preparing them | SCHERING CORPORATION (US) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047094-A1 | Tricyclic carbapenem compounds | OXA1L, GNE, MGAM | SMN1; SMN2 711/4885RAB9A 3412/4885NPC1 3188/4885 |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | SMN1; SMN2 3999/4885RAB9A 1597/4885NPC1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.